Real World Data and Evidence: Support for Drug Approval: Applications to Kidney Diseases.
作者信息
Thompson Aliza M, Southworth Mary Ross
机构信息
Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
出版信息
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1531-1532. doi: 10.2215/CJN.02790319. Epub 2019 Sep 6.
Abstract
摘要
相似文献
1
Real World Data and Evidence: Support for Drug Approval: Applications to Kidney Diseases.真实世界数据与证据：对药物批准的支持：在肾脏疾病中的应用
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1531-1532. doi: 10.2215/CJN.02790319. Epub 2019 Sep 6.
2
Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.关于在美国新药申请中使用外部分期临床试验数据的监管和科学问题：FDA 的观点。
Clin Pharmacol Ther. 2013 Aug;94(2):230-42. doi: 10.1038/clpt.2013.70. Epub 2013 Apr 3.
3
Dermatology clinical trials and drug development.皮肤病学临床试验与药物研发。
Dermatol Nurs. 2003 Oct;15(5):428-34.
4
Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.2009-2018 年获美国食品和药物管理局加速批准的治疗性药物的批准后试验与关键试验持续时间比较。
JAMA Netw Open. 2021 Nov 1;4(11):e2133601. doi: 10.1001/jamanetworkopen.2021.33601.
5
US new drug applications increasingly rely on trials conducted abroad.美国的新药申请越来越依赖于在国外进行的试验。
BMJ. 2010 Jul 6;341:c3616. doi: 10.1136/bmj.c3616.
6
Innovative design and analysis for rare disease drug development.创新设计与罕见病药物开发分析。
J Biopharm Stat. 2020 May 3;30(3):537-549. doi: 10.1080/10543406.2020.1726371. Epub 2020 Feb 17.
7
Statistical considerations for rare diseases drug development.罕见病药物研发的统计学考量
J Biopharm Stat. 2019;29(5):874-886. doi: 10.1080/10543406.2019.1657441. Epub 2019 Aug 27.
8
Using real-world safety data in regulatory approval decisions: Sotagliflozin and the risk of diabetic ketoacidosis.在监管审批决策中使用真实世界安全性数据：索格列净与糖尿病酮症酸中毒风险
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1322-1324. doi: 10.1002/pds.4994. Epub 2020 Mar 18.
9
The FDA Breakthrough-Drug Designation - Four Years of Experience.美国食品药品监督管理局突破性药物认定——四年经验
N Engl J Med. 2018 Apr 12;378(15):1444-1453. doi: 10.1056/NEJMhpr1713338.
10
Drug pipeline: Q310.药物研发流程：2010年第三季度
Nat Biotechnol. 2010 Oct;28(10):998. doi: 10.1038/nbt1010-998.
引用本文的文献
1
Future Designs of Clinical Trials in Nephrology: Integrating Methodological Innovation and Computational Power.肾脏病学临床试验的未来设计：整合方法学创新与计算能力
Sensors (Basel). 2025 Aug 8;25(16):4909. doi: 10.3390/s25164909.
2
Diagnostic Validity of Chronic Kidney Disease in Health Claims Data Over Time: Results from a Cohort of Community-Dwelling Older Adults in Germany.健康声明数据中慢性肾脏病诊断有效性的长期研究：来自德国一组社区居住老年人的队列研究结果
Clin Epidemiol. 2024 Feb 22;16:143-154. doi: 10.2147/CLEP.S438096. eCollection 2024.
3
The Lack of a Standardized Definition of Chronic Dialysis Treatment in German Statutory Health Insurance Claims Data.德国法定健康保险索赔数据中缺乏对慢性透析治疗的标准化定义。
Dtsch Arztebl Int. 2024 Mar 8;121(5):148-154. doi: 10.3238/arztebl.m2024.0015.
4
Emulation of the control cohort of a randomized controlled trial in pediatric kidney transplantation with Real-World Data from the CERTAIN Registry.利用 CERTAIN 注册研究的真实世界数据对儿科肾移植随机对照试验的对照队列进行模拟。
Pediatr Nephrol. 2023 May;38(5):1621-1632. doi: 10.1007/s00467-022-05777-x. Epub 2022 Oct 20.
5
Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data.在行政索赔数据中识别中度至重度慢性肾脏病诊断的准确性。
Pharmacoepidemiol Drug Saf. 2022 Apr;31(4):467-475. doi: 10.1002/pds.5398. Epub 2021 Dec 23.
6
Community pharmacists' knowledge, perceptions, and practices about topical corticosteroid counseling: A real-world cross-sectional survey and focus group discussions in Korea.社区药剂师关于局部用皮质类固醇药物咨询的知识、认知及实践：韩国一项真实世界横断面调查与焦点小组讨论
PLoS One. 2020 Jul 29;15(7):e0236797. doi: 10.1371/journal.pone.0236797. eCollection 2020.
Zotero 插件